End of year letter to shareholders

0

BERLIN,, 22 December 2021 / CNW / – Greenrise Global Brands Inc. (Frankfurt: C4T) (ISIN: CA39540L1085) (CSE: XCX) (“Greenrise Global”) is pleased to present a year-end letter to its shareholders.

Dear shareholder friends,

germany the time has come.

The formation of the German government this month confirmed that recreational cannabis for adult use will become a reality in the near future, which Germany the first country in the Group of Seven (G7) European Union to fully legalize the medical, CBD and recreational use of cannabis.

Greenrise Global Brands is one of the few listed companies to focus on cannabis in Germany. Our strategy is to be a leader in all legal parts of cannabis in Germany through our wholly owned subsidiaries, Greenrise Life GmbH, Greenrise (Wellbeing) GmbH and AMP Alternative Medical Products GmbH.

We formed Greenrise Life to lead our efforts to enter the recreational use market. Over the coming year, Greenrise Life will strive to support the policy as the German government enacts the required laws and policies. AMP’s national sales team distributes medical cannabis products to clinics and pharmacies and can play an important role in the distribution of recreational cannabis to consumers if pharmacies are considered a potential licensed dispensary.

To move the discussion forward, the next installment of Greenrise in its Cannabis Roundtable Series to be released in early 2022 will discuss the new government’s approach to recreational cannabis with members of coalition parties and moderated by Dr Wieland Schinnenburg, MdB, a former spokesperson for drugs and addiction policy for the Free Democratic Party (FDP) and a highly respected expert on medical cannabis.

During the year, Greenrise Wellbeing, our CBD cannabis and wellness affiliate, launched Herbify, a brand of CBD oral cosmetics sold online and Canavex® which is designed to be taken with prescriptions for medical cannabis and sold in pharmacy and drugstore next year. Greenrise Wellbeing anticipates strong consumer demand for CBD wellness products in the coming years as there will be clarity on which products can be sold in Germany that meet the EU authorization for novel foods.

Greenrise Wellbeing’s goal for next year is to dramatically increase sales through its brands’ online and retail channels and to strategically acquire brands of CBD that are financially profitable and meet the requirements of authorization of novel foods in Germany.

Greenrise’s medical cannabis subsidiary, AMP, has built a solid reputation for providing German patients with the highest quality medical cannabis products available. AMP’s strength lies in its frontline relationships with physicians and pharmacies, the only point of sale for medical cannabis to patients.

AMP has assembled a specially trained national sales team to sell medical cannabis products, which generated approximately € 500,000 in sales in its first year as an operating company selling Aphria and Bedrocan flowers as well. as extracts from Aphria and Little Green Pharma. AMP will launch its Dronabinol product on the market early next year alongside other pharmaceuticals as the medical market moves away from the flower.

The pandemic affected the ability of our sales team to meet with physicians whose time was either limited or limited due to this particular situation. AMP’s goal over the next year is to ensure it has a sufficient supply of products and to continue training its sales team to meet the expected prescription demand when the pandemic resides temporarily or definitively. AMP continues to invest and advance its research into the efficacy and safety of medical cannabis with Waldhausklinik Deuringen gGmbH, a not-for-profit acute-care clinic for internal medicine in the Free State of Bavaria, to promote continuing education for physicians.

We would like to thank our shareholders for their continued support.

Seasonal greetings to you and your family, and best wishes for the New Year.

Cordially,

Dr Stefan Feuerstein Hendrik knopp
President and Managing Director

About Greenrise Global Brands

Greenrise Global helps people realize the beneficial properties of cannabis. Greenrise Global is a publicly traded Canadian company with two German operating subsidiaries: Greenrise GmbH (“Greenrise Wellbeing”) and AMP Alternative Medical Products GmbH (“AMP”). Greenrise Wellbeing is a CBD wellness company based in Hamburg, with brands including Herbify and CANAVEX® in his wallet.

AMP is based in Erfurt and supplies medical cannabis products to pharmacies across Germany, including the medical cannabis brands of Aphria, Bedrocan, Little Green Pharma and CHA product line branded and sold by its national sales team. The AMP complies with the German Narcotics Act (BtMG) and the regulatory requirements of the Free State of Thuringia, ensuring that products imported from all over the world and sold in Germany meet the European Union Good Manufacturing Practices (EU-GMP) standard.

For more information on Greenrise Global, please visit www.greenriseglobal.com

About the Greenrise Cannabis Roundtable Series

Episodes of the Round Table series are available at: www.amp-eu.de/roundtable (in German with English subtitles), on the Greenrise YouTube channel and on all major podcast platforms (in German).

FOLLOW US ON:

Twitter: https://twitter.com/GreenriseGlobal
LinkedIn: https://linkedin.com/company/greenriseglobal/
Instagram: https://www.instagram.com/greenriseglobal/

Neither CSE nor its regulatory services provider (as that term is defined in CSE policies) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and their calendar. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company does not undertake to update them publicly to reflect new information or the occurrence of future events or circumstances, unless the law does not require otherwise.

SOURCE Greenrise Global Brands Inc.

For more information: CONTACT GREENRISE: Hendrik Knopp, Director, [email protected], +1 236-833-1602; Media inquiries: Valeria Bravo, Corporate Communications and Media, [email protected], +1 604-689-7533



Source link

Share.

Comments are closed.